Enzolytics Inc. (ENZC) Stock

About Enzolytics Inc.

Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV).

Enzolytics Inc. (ENZC) stock trades at $0.00 with a market capitalization of $2.36M. The stock is valued at a negative price-to-earnings (P/E) ratio of -11.20, reflecting a net loss over the last twelve months, a negative price-to-book of -0.02, reflecting negative shareholders' equity, price-to-sales of 0.00.

On profitability, Enzolytics Inc. generates a return on equity (ROE) of 0.00% (not meaningful, as shareholders' equity is negative), return on capital employed of 0.14%.

Official website: enzolytics.com